Join us in revolutionizing chronic pain treatment with proven, non-opioid solutions that address a critical, underserved market.
Alyea Therapeutics is poised to redefine chronic pain treatment with its innovative non-opioid solutions. With LDN progressing through regulatory approval and the Alyea Clear Patch technology expanding market opportunities, the company is at a pivotal stage for growth.
Investors have a unique opportunity to support a breakthrough approach to pain management that addresses a critical, underserved market.
Dr. Soin is a nationally recognized thought leader and innovator in pain management, dedicated to advancing safe, non-opioid solutions for chronic pain. He has served as President of the American Society of Interventional Pain Physicians and several other national and state organizations, helping shape clinical standards and policy. Dr. Soin holds five academic degrees–including from Dartmouth and Brown–and has authored a medical textbook and more than 100 peer-reviewed publications. He holds several dozen global patents for medical devices and pharmaceutical compounds aimed at breaking the cycle of opioid dependence. A former President of the Ohio Medical Board, Dr. Soin played a key role in passing statewide opioid regulations. His leadership continues to drive Alyea’s mission to redefine pain care through innovation and compassion.
Tony brings over 30 years of leadership in biotechnology, drug development, and translational science. He has held executive roles across multiple life sciences companies, where he successfully advanced therapies from early-stage discovery into clinical trials. With more than 20 U.S. patents, Tony work spans neurodegenerative diseases, oncology, and cardiovascular health. He has a strong track record of securing funding and building research-driven organizations. Prior to joining us, he served as President and CEO of NeuroTherapia and Abcon Therapeutics. Tony holds a Ph.D. in Molecular Genetics from The Ohio State University.
Russ Belden brings over 37 years of biotech commercialization and operational leadership experience, with a focus on guiding emerging biotech companies from preclinical stages to first launch. He began his career at Genentech, where he played a pivotal role in launching their BioOncology franchise–including Rituxan and Herceptin–and rose to become Director of Hematology Sales. As Founder and CEO of Bridge, Russ has supported more than 125 early-stage biotech companies, delivering hands-on commercialization strategy and interim leadership. He is also a recognized educator, having co-developed industry courses on drug valuation and commercialization readiness. Russ holds a B.S. in Pharmacy from the University of New York at Buffalo.
Dr. Sinclair is a renowned pharmaceutical executive and an influential figure in the field of addiction treatment, best known for founding Opiant Pharmaceuticals, Inc. (formerly Lightlake Therapeutics, Inc.). With a distinguished background in medicine and extensive experience in pharmaceutical development, he has played a pivotal role in addressing the global opioid crisis through innovative therapeutic solutions. Dr. Sinclair earned his medical degree from London University/Middlesex Hospital and has cultivated a rich career in healthcare and pharmaceutical sciences. His academic pursuits laid the groundwork for his deep understanding of addiction and mental health disorders, that would later guide his professional journey.
Mr. Danziger, CPA, is a seasoned financial executive and public markets advisor with over four decades of experience in audit, compliance, and corporate governance. Most recently, he served as Senior Vice President, Assurance and National Leader of Public Companies at MNP LLP, Canada’s 5th largest accounting firm, where he led audit teams across North America and advised companies navigating public market transactions. A Chartered Professional Accountant, Mr. Danziger has served on numerous corporate boards, including TSX-, Nasdaq-, and LSE-listed firms, and has deep expertise in complex financial reporting, governance, and turnaround strategies. He currently sits on several boards and advisory committees, including the TSXV Advisory Committee.
Peter Tassiopoulos has been a director of Alyea since immediately following its inception. He also has been the Chief Executive Officer of the Company since August 2024. From April 4, 2022, until his appointment as Chief Executive Officer, he served as an independent mergers and acquisitions (M&A) consultant, consulting for various companies. During that time, he restructured in excess of $150 million in debt and facilitated a $35 million asset purchase for a Canadian public company. Prior to that, from March 2013 through December 1, 2014, Mr. Tassiopoulos served as the Chief Executive Officer of Sphere 3D Corp. (Nasdaq: ANY), and then, from December 1, 2014 until November 14, 2018, as its President, and, from November 14, 2018 to April 2022, as its Chief Executive Officer again. Mr. Tassiopoulos has over 30 years of leadership experience across healthcare, finance, and technology sectors and has successfully completed over $1 billion in M&A, divestitures, and financing transactions throughout his career. Mr. Tassiopoulos has led teams in executing complex transactions with a focus on mergers and acquisitions, capital market strategies, and strategic relationships with industry experience spanning cryptocurrency, technology, IT, healthcare, and gaming.
Tony Isaac is an officer of and director of Alyea since inception and will remain as a director after the formal appointment of Dr. Soin as chief executive officer. He also has been a director of the Company since May 2015, served as its President since May 2015, and served as its Chief Executive Officer from May 2016 until August 2024; he also became its Corporate Secretary in 2021 and served as its Interim Chief Executive Officer from February 2016 until May 2016. Mr. Isaac has served as Financial Planning and Strategist/Economist of Live Ventures Incorporated (Nasdaq: LIVE), a holding company for diversified businesses, since July 2012. He is the Chairman and Co-Founder of Isaac Organization, a privately held investment company. Mr. Isaac has invested in various companies, both private and public from 1980 to present. Mr. Isaac’s specialty is negotiation and problem-solving of complex real estate and business transactions. Mr. Isaac has served as a director of Live Ventures since December 2011. Mr. Isaac graduated from Ottawa University in 1981, where he majored in Commerce and Business Administration and Economics.
Ms. Pendergast is an expert in the regulatory aspects of drug development and is President of Pendergast Consulting, a consulting firm that advises biopharmaceutical companies, patient groups, professional and advocacy organizations, governments, and academic and financial institutions. Prior to founding her own firm, she was the Executive Vice President of Government Affairs at Elan Corporation from 1998 to 2003. Ms. Pendergast also spent more than 18 years at the US Food and Drug Administration (“FDA”), serving as Deputy Commissioner and Senior Advisor to the FDA Commissioner and Associate Chief Counsel for Enforcement. Ms. Pendergast has served as a director of a number of private and public companies.
LDN is a non-opioid treatment that works by modulating pain pathways and reducing inflammation rather than masking symptoms. Unlike opioids, it has no risk of addiction or dependence and provides long-term relief without severe side effects.
LDN has received FDA orphan drug designation for the treatment of Complex Regional Pain Syndrome (CRPS) and is currently advancing through clinical trials toward full regulatory approval. LDN is NOT FDA approved and Alyea’s version is still investigational and in clinical trials.
Alyea Clear Patch is a topical pain relief technology designed for targeted, localized treatment. It delivers non-invasive pain relief that is customizable to the location of pain. It allows for localized treatments without a lot of systemic absorption.
Alyea’s solutions are designed for patients suffering from chronic pain conditions such as CRPS for LDN and other inflammatory pain disorders for the clear patch, especially those seeking non-opioid alternatives.
Invest in innovative, non-opioid treatments that address a critical, underserved market.
Get In Touch
